en · de · es · fr · pt
melanotan-2-notes.peptides6908.com › Guide › Melanotan-2 Identity And Regulatory Status — Explained

Melanotan-2 Identity And Regulatory Status — Explained

By Editorial Desk · published 2026-02-15 · last reviewed 2026-03-13 · Guide

This is a working overview of melanocortin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-03-13. Anything still debated is marked as such rather than presented as settled.

Melanotan-2 Identity And Regulatory Status

Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.

Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.

Handling, Measurement, and Regulatory Context

Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.

Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.

Melanotan-2 at a glance

PropertyValueNotes
Chemical classSynthetic cyclic heptapeptideAnalogue of alpha-melanocyte-stimulating hormone
Common synonymsMT-II; melanotan 2No internationally accepted non-proprietary name
Typical presentationLyophilised powder in a sealed vialOften supplied alongside a separate diluent
Regulatory statusUnapproved therapeutic substanceCustoms seizure reported in several jurisdictions
Reported route in useSubcutaneous injectionSelf-administered outside clinical settings

Identity and Chemical Background

Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.

The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.

Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.

Related pages on this site

Regulatory Status and Literature Discussion

Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.

Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.

Peptide Identity and Structural Background

Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.

The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.

Notes from published material

== Early life and education == Frederick Sanger was born on 13 August 1918 in Rendcomb, a small village in Gloucestershire, England, the second son of Frederick Sanger, a general practitioner, and his wife, Cicely Sanger (née Crewdson). He was one of three children. His brother, Theodore, was only a year older, while his sister May (Mary) was five years younger. His father had worked as an Anglican medical missionary in China but returned to England because of ill health. He was 40 in 1916 when he married Cicely, who was four years younger. Sanger's father converted to Quakerism soon after his two sons were born and brought up the children as Quakers. Sanger's mother was the daughter of an affluent cotton manufacturer and had a Quaker background, but was not a Quaker. When Sanger was around five years old the family moved to the small village of Tanworth-in-Arden in Warwickshire. The family was reasonably wealthy and employed a governess to teach the children. In 1927, at the age of nine, he was sent to the Downs School, a residential preparatory school run by Quakers near Malvern. His brother Theo was a year ahead of him at the same school. In 1932, at the age of 14, he was sent to the recently established Bryanston School in Dorset. This used the Dalton system and had a more liberal regime which Sanger much preferred. At the school he liked his teachers and particularly enjoyed scientific subjects.

where ρ is the resistivity; i.e. the resistance R is inversely proportional to the cross section area S of the resistor. The reason why Poiseuille's law leads to a different formula for the resistance R is the difference between the fluid flow and the electric current. Electron gas is inviscid, so its velocity does not depend on the distance to the walls of the conductor. The resistance is due to the interaction between the flowing electrons and the atoms of the conductor. Therefore, Poiseuille's law and the hydraulic analogy are useful only within certain limits when applied to electricity. Both Ohm's law and Poiseuille's law illustrate transport phenomena.

==== Difficulties with interpretation of TSH measurement ==== Heterophile antibodies (which include human anti-mouse antibodies (HAMA) and Rheumatoid Factor (RF)), which bind weakly to the test assay's animal antibodies, causing a higher (or less commonly lower) TSH result than the actual true TSH level. Although the standard lab assay panels are designed to remove moderate levels of heterophilic antibodies, these fail to remove higher antibody levels. "Dr. Baumann [from Mayo Clinic] and her colleagues found that 4.4 percent of the hundreds of samples she tested were affected by heterophile antibodies.........The hallmark of this condition is a discrepancy between TSH value and free T4 value, and most important between laboratory values and patient's conditions. Endocrinologists, in particular, should be on alert for this." Macro-TSH - endogenous antibodies bind to TSH reducing its activity, so the pituitary gland would need to produce more TSH to obtain the same overall level of TSH activity. TSH Isomers - natural variations of the TSH molecule, which have lower activity, so the pituitary gland would need to produce more TSH to obtain the same overall level of TSH activity. The same TSH concentration may have a different meaning whether it is used for diagnosis of thyroid dysfunction or for monitoring of substitution therapy with levothyroxine. Reasons for this lack of generalisation are Simpson's paradox and the fact that the TSH-T3 shunt is disrupted in treated hypothyroidism, so that the shape of the relation between free T4 and TSH concentration is distorted.

Sources: en.wikipedia.org

Background from the literature

Astrochicken is the name given to a thought experiment Dyson expounded in his book Disturbing the Universe (1979). He contemplated how humanity could build a small, self-replicating automaton that could explore space more efficiently than a crewed craft could. He attributed the general idea to John von Neumann, based on a lecture von Neumann gave in 1948 titled The General and Logical Theory of Automata. Dyson expanded on von Neumann's automata theories and added a biological component.

The French Laundry event took place on November 6, and between November 5 and December 7 over 442,000 new signatures were submitted and verified; 1,664,010 verified signatures, representing roughly 98% of the final total of 1,719,900, were submitted between November 2020 and March 17, 2021. In response to the criticism, Newsom said in a statement, "While the First Partner and I followed the restaurant's health protocols and took safety precautions, I should have modeled better behavior and not joined the dinner." During the campaign, Newsom compared the recall effort to the attempts to overturn the 2020 United States presidential election. On September 14, 2021, the recall election was held, and only 38% voted to recall Newsom, so he remained in office.

At a meeting of the Pheu Thai Party on 20 March 2022, Paetongtarn was elected as "Head of the Pheu Thai Family". When speaking at the Pheu Thai Party's annual general meeting in April 2022, she said that she wanted to see regime change in Thailand and wanted to gain more experience before standing for the post of the country's prime minister. Paetongtarn became the leading prime minister-candidate in the opinion polls. In April 2023, she was officially nominated as one of the three prime minister-candidates of Pheu Thai Party for the general election, along with Srettha Thavisin and Chaikasem Nitisiri. After the general election in May 2023, the Pheu Thai Party secured the second-highest number of seats in the House of Representatives, following the Move Forward Party. She expressed disappointment that the party did not achieve first place as planned but stated that she was ready to work with the Move Forward Party and other parties willing to form a coalition with both parties. However, after Pheu Thai Party withdrew from the memorandum of understanding to form a government with the Move Forward Party, on 9 August, she and Pheu Thai Party executives walked from the OAI Tower, where the party's headquarters are located, to the neighbouring Thai Summit Tower to discuss with the Move Forward Party leaders about endorsing a candidate for the third round of prime ministerial voting.

Sources: en.wikipedia.org

Reference notes

=== Breath tests === Breath test for microbial diagnosis on patients has been used in a clinical setting for bacteria, including Helicobacter pylori. Diagnostic test using the breath of patients look for metabolites excreted that were manufactured by the infectious microorganism. H. pylori is tested by testing patients for CO2 concentration, increased because of the organism's ability to convert urea into other derivatives.

In the early months of 2010, the economic crisis worsened due to the outbreak of the European debt crisis initiated by the Greek government-debt crisis. Immediately, the debt of the rest of the Eurozone countries which, as in the case of Spain, presented a strong deficit in their balance of payments began to be "attacked" in the financial markets with the consequent increase of the risk premium with respect to the German bond. Then the creditor countries of the Eurozone, led by Germany, imposed on the debtors to decrease their public spending to reduce the budget deficit. The European institutions' ultimatum to the Spanish government came at the European Council meeting of May 9, 2010. Three days later, on May 12, Prime Minister Rodríguez Zapatero announced in Congress a drastic cut in public spending to the tune of 15 billion euros – civil servants' salaries were reduced by 5%, pensions were frozen, investment in infrastructure was paralyzed, among other measures – thus consummating the turn of the Socialist government's economic policy towards "adjustment" policies. The consequence was to nip the incipient recovery in the bud and cause the fall into a new recession at the end of 2011, with the consequent increase in unemployment.

=== Client-side options === A LIMS has utilized many architectures and distribution models over the years. As technology has changed, how a LIMS is installed, managed, and utilized has also changed with it. The following represents architectures which have been utilized at one point or another.

The age of the Earth is 4.54 Gya as found by radiometric dating of calcium-aluminium-rich inclusions in carbonaceous chrondrite meteorites, the oldest material in the Solar System. Earth, during the Hadean eon (from its formation until 4.031 Gya,) was at first inhospitable to life. During its formation, the Earth lost much of its initial mass, and so lacked the gravity to hold molecular hydrogen and the bulk of the original inert gases. Soon after initial accretion of Earth at 4.48 Gya, its collision with Theia, a hypothesised impactor, is thought to have created the ejected debris that eventually formed the Moon. This impact removed the Earth's primary atmosphere, leaving behind clouds of viscous silicates and carbon dioxide. This unstable atmosphere was short-lived, soon condensing to form the bulk silicate Earth, leaving behind an atmosphere largely consisting of water vapor, nitrogen, and carbon dioxide, with smaller amounts of carbon monoxide, hydrogen, and sulfur compounds. The solution of carbon dioxide in water is thought to have made the seas slightly acidic, with a pH of about 5.5. Condensation to form liquid oceans is theorised to have occurred as early as the Moon-forming impact. This scenario is supported by the dating of 4.404 Gya zircon crystals with high δ18O values from metamorphosed quartzite of Mount Narryer in Western Australia. The Hadean atmosphere has been characterized as a "gigantic, productive outdoor chemical laboratory," similar to volcanic gases today which still support some abiotic chemistry.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan II approved for medical use?

No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.

Where did melanotan II originate?

It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.

Why is purity a concern for unapproved peptides?

Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.

How is a sample checked for identity?

Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.

Network